ArticleCureus2025
A Comparative Study on Clinical Efficacy of Clobetasol and Betamethasone in Orabase in Combination With Clotrimazole in the Management of Oral Lichen Planus.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextOral lichen planus (OLP) is a chronic inflammatory mucocutaneous disease characterized by pain and burning sensation. As etiology remains unclear, the treatment of OLP is focused mainly on reducing symptoms through modulation of local immune response.
aimsThe aim of this study is to evaluate and compare the clinical efficacy of Clobetasol 0.05% orabase and Betamethasone 0.05% orabase, both combined with Clotrimazole 1%, in managing symptomatic OLP. METHODOLOGY: A double-blind, randomized clinical trial was conducted on 30 patients diagnosed with OLP at a tertiary dental hospital. Patients were randomly divided into two groups: Group A (Clobetasol + Clotrimazole) and Group B (Betamethasone + Clotrimazole). Clinical response was assessed at two and four weeks using the Global Assessment Scale for lesion size and the visual analogue scale (VAS) for burning sensation. The collected data were analyzed using IBM SPSS Statistics for Windows, Version 17 (Released 2009; IBM Corp., Armonk, New York, United States).
resultsAt the end of four weeks, the change in mean size obtained was score 2.0±0.95 in Group A and 1.66±1.4 in Group B (p-value = 0.51), indicating that both the study drugs had a similar decrease in the global assessment of efficacy scores with no significant statistical difference. Mean change in the VAS score at the end of four weeks revealed a decrease in the mean score of 4.66±2.30 in Group A and a decrease by 4.00±1.80 score in Group B (p-value=0.44), indicating no statistical significance.
conclusionsBoth clobetasol and betamethasone demonstrated comparable efficacy in reducing pain and lesion size among patients with OLP. This finding suggests that either regimen can serve as a viable therapeutic option in the management of OLP. Considering their similar clinical outcomes, the choice between these corticosteroids may depend on factors such as drug availability, patient tolerance, cost, and physician preference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.